Panacea Biotec informs about updates

17 May 2021 Evaluate

Panacea Biotec has informed that the Company has instituted a suit before the Hon'ble Delhi High Court seeking to restrain Sanofi Healthcare India from marketing a fully liquid hexavalent vaccine that would infringe Company's patent for its fully liquid Whole Cell Pertussis based fully liquid Hexavalent Vaccine, EasySix. Panacea Biotec's EasySix is a first of its kind Whole Cell Pertussis based fully liquid Hexavalent Vaccine which comes in a pre-filled syringe and is used to vaccinate against, Diphtheria, Tetanus, Whooping Cough, Hepatitis B, Haemophilus influenza type b and Inactivated Polio (DTwP-HepB-Hib-IPV). EasySix has been in the market since 2017. A brief note in respect of the above-mentioned matter is enclosed for information and record.

The above information is a part of company’s filings submitted to BSE.

Panacea Biotec Share Price

520.10 -25.05 (-4.60%)
05-May-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1835.15
Dr. Reddys Lab 1172.50
Cipla 1543.10
Lupin 2087.30
Zydus Lifesciences 892.15
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...